Compounded Sema Injectable denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Compounded Semaglutide as Duplicate Therapy

A "duplicate therapy" denial means Cigna's system detected that you are already receiving, or have recently received, a GLP-1 receptor agonist — either FDA-approved semaglutide (branded) or another agent in the same drug class — and concluded that adding or substituting a compounded semaglutide formulation would result in overlapping coverage of the same therapeutic mechanism. Cigna applies this denial to prevent concurrent use of two drugs with the same pharmacological class.

## Why This Is Appealable

This denial is often based on automated claim-screening that does not capture the full clinical picture. Common situations where an appeal succeeds: the previously dispensed agent was discontinued before the compounded product was prescribed (a gap in the records or in Cigna's data); the two products are not in fact being used concurrently; or the prescriber is transitioning the patient between agents and the overlap is intentional and clinically justified. Because compounded semaglutide is itself not an FDA-approved product, the appeal must also navigate that separate coverage dimension — but the duplicate-therapy basis can still be rebutted on the facts.

## The Federal Appeal Framework

• Internal appeal: File under ERISA Section 503 or ACA Section 2719 within the deadline in your denial notice (commonly 180 days). Cigna must decide a pre-service internal appeal within 30 days and a post-service claim within 60 days.
• External review: After the internal appeal is exhausted, request independent external review under ACA Section 2719 — generally within four months of the final denial notice. The IRO reviews clinical necessity independently of Cigna's formulary and duplicate-therapy rules.
• Expedited option: Request expedited internal and external review if a standard timeline would seriously jeopardize your health or your ability to maintain ongoing treatment.

## Documentation to Gather

• Prescription and dispense history: Records showing exactly which agents were dispensed, on what dates, and for what duration — demonstrating whether true concurrent use occurred.
• Discontinuation documentation: If a prior GLP-1 agent was stopped, a prescriber note or pharmacy record confirming the stop date, and the reason for stopping (e.g., intolerance, inadequate response, shortage).
• Prescriber medical-necessity letter: Explaining the clinical rationale for prescribing the compounded formulation, confirming it is not being used concurrently with another agent in the same class, and rebutting the duplicate-therapy basis point by point.
• Diagnosis confirmation: Chart documentation of the underlying condition (e.g., type 2 diabetes, obesity) and its severity.
• Prior treatment history: A timeline of all GLP-1 and related agents tried, with dates, doses, and outcomes — establishing the treatment narrative.

## Criteria-Mapping Structure

Obtain Cigna's coverage policy for GLP-1 agents and its duplicate-therapy/concurrent-use rules. For each basis cited:

| Cigna Duplicate-Therapy Criterion | Chart Evidence | |---|---| | Active concurrent GLP-1 claim on file | Pharmacy records showing no active overlap | | Same pharmacological class | Prescriber note on agent selection rationale | | Transition or substitution vs. addition | Prescriber letter explaining clinical transition plan |

Note: Because the product in question is a compounded formulation, also review Cigna's separate coverage position on compounded drugs — addressing both the duplicate-therapy basis and the compound-coverage basis in a single appeal letter is more efficient.